Health Care · In Vitro & In Vivo Diagnostic Substances

TKNO Alpha Teknova, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 185090238 filings
Russell 2000

TKNO at a glance

Alpha Teknova, Inc. (TKNO, SEC CIK 1850902) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as July 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Alpha Teknova, Inc. (TKNO) reported revenue of $40.5 million (up 7.4% from FY2024) and a net loss of $17.3 million. Diluted EPS was -$0.32.
  • As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Alpha Teknova, Inc. (TKNO) shares worth $37.7 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Gunstream Stephen on March 6, 2026 of 26,000 shares at $2.15 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$40.5M
+7.4% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
23 funds
$37.7M · +5 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Custom manufacturing of critical reagents for life sciences, supporting research to commercialization stages
  • New emphasis on scaling operations with investment in a new warehouse and distribution facility to improve capacity and efficiency
  • Strategic shift: Growth focus through targeted marketing, strategic partnerships, and expanded sales efforts to increase brand awareness and market presence
  • Revenue $40.5M in 2025, up $2.8M (7.4%) from 2024; operating loss narrowed to $17.0M from $26.1M in prior year
  • Entered $28.245M amended credit facility in March 2025, including $23.245M term loan and $5M working capital, with revenue and cash covenants

Risk Factors

  • Regulatory risk: compliance with Second Amended and Restated Credit Agreement net revenue covenant of $39.0M for 2025, minimum cash requirement $8.0M
  • Macroeconomic exposure: 94.4% of revenue from U.S. customers, limited international diversification with only $2.3M (5.6%) sales outside U.S. in 2025
  • Operational risk: reliance on manufacturing efficiency gains to improve gross margin to 33.2% in 2025 from 26.5% adjusted in 2024
  • Competitive risk: reduced R&D spend by 20.4% to $2.2M in 2025 vs $2.8M in 2024, potentially impacting innovation versus peers
  • Financial risk: $13.2M outstanding term loan with related $1.1M exit fee and total accumulated deficit of $135.8M as of December 31, 2025

AI summary of the TKNO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $12.7M, up 21.5% YoY from $10.5M
  • Gross margin 38.0% vs 30.7% YoY, operating loss $3.2M vs $4.0M
  • Clinical Solutions $3.2M, up 85.7% YoY, best-performing category
  • Operating cash use $5.1M vs $8.2M YoY, capital expenditures $0.5M
  • $42.9M October offering proceeds, inflation, tariffs, interest rates and demand timing headwinds

Risk Factors

  • New AI risk: planned use in manufacturing and quality systems creates model-error, data-leakage, and product-quality exposure
  • New regulatory risk: California AI laws may require technology changes, higher compliance costs, or trigger penalties
  • New market risk: October 2026 offering added 9,200,000 freely tradable shares, increasing potential price pressure
  • New compliance risk: emerging-growth-company status ends December 31, 2026, adding reporting obligations
  • Financial risk: net losses totaled $11.2 million for the nine months ended September 30, 2026

AI summary of the TKNO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter fiscal 2026 results announced for period ended September 30, 2026
  • Full financial results and management commentary contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $12.7M, up 22%, with Clinical Solutions up 86% to $3.2M
  • Gross margin improved to 38.0% from 30.7%, while operating expenses increased to $8.0M
Filed Oct 21, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $40 million gross equity raise through 8,000,000 shares at $5.00 per share
  • Underwriters pay $4.70 per share, implying $2.40 million in underwriting discounts before other expenses

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 estimated revenue $12.5M-$12.7M, providing preliminary evidence of quarterly operating scale
  • Gross margin estimated at 36.0%-38.0%, relevant to profitability and pricing trends

Item 8.01: Other Events

  • Offering launch and pricing announcements indicate a capital raise, with terms contained in Exhibits 99.1 and 99.2
  • Updated investor presentation may include revised strategy, operating outlook, or offering-related information

Item EX-99.1: Item EX-99.1

  • Proposed underwritten common-stock offering, creating potential shareholder dilution
  • Underwriters may purchase up to an additional 15% of offered shares through a 30-day option

Item EX-99.2: Item EX-99.2

  • $40 million gross equity offering: 8,000,000 shares priced at $5.00 each
  • Potential additional dilution from underwriters’ 30-day option for 1,200,000 shares

Item EX-99.3: Item EX-99.3

  • 2026 revenue guidance raised to $45M-$47M, representing 14% growth at midpoint
  • Free Cash Outflow targeted below $8M, with cash and short-term investments of $17.4M at June 30, 2026
Filed Aug 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $12.2M, up 18%, with Lab Essentials and Clinical Solutions each growing 18%
  • 2026 revenue guidance raised to $45–47M, signaling sustained demand and improved confidence in biotech-market recovery

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 announced August 5, 2026
  • Financial details and management commentary available in Exhibit 99.1 press release

AI summaries of TKNO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TKNO

Don't miss the next TKNO filing

  • Alerts as it files. A push when TKNO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TKNO, by share count.
  • Ask anything. An AI agent that reads every TKNO filing and answers with sources.

TKNO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
DEMSKI MARTHA JJJul 14, 2026-
DEMSKI MARTHA JJJul 14, 2026-
DEMSKI MARTHA JAJun 1, 2026-
Vos AlexanderAJun 1, 2026-
ROBERTSON BRETTAJun 1, 2026-
Gunstream StephenBuyMar 6, 2026$2.15
Lowell MatthewBuyMar 6, 2026$2.19
Terrill DamonAFeb 15, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$37.7M$40.5M
Gross Profit-$7.2M$13.4M
Operating Income--$26.1M-$17.0M
Net Income--$26.7M-$17.3M
Gross Margin-19.2%33.2%
Op. Margin--69.3%-41.9%
Net Margin--70.9%-42.6%
Balance Sheet
Total Assets$128.6M$118.8M$103.6M
Equity$90.0M$82.4M$68.8M
ROE--32.5%-25.1%
Per Share
EPS-$-0.57$-0.32
Cash Flow
Operating CF--$12.4M-$8.6M
CapEx-$1.1M$1.1M

Source: XBRL data in Alpha Teknova, Inc. (TKNO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TKNO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TKNO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202623$37.7M
Q2 202618$21.5M
Q1 202619$7.7M
Q4 202516$8.4M
Q3 202515$13.6M
Q2 202518$13.8M
Q1 202514$7.1M
Q4 20249$16.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 132 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TKNO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 4, 2026Analysis-
8-KOct 21, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 5, 2026Analysis-
4Jul 16, 2026--
4Jun 2, 2026-
4Jun 2, 2026-
4Jun 2, 2026-
8-KJun 1, 2026Analysis
10-QMay 7, 2026Analysis
8-KMay 6, 2026Analysis
4Mar 9, 2026--
4Mar 9, 2026--
4Mar 9, 2026--
10-KMar 2, 2026Analysis
8-KFeb 26, 2026Analysis-
10-QNov 7, 2025Analysis
10-QAug 8, 2025-
10-QMay 9, 2025-
10-KMar 7, 2025-
10-QNov 8, 2024-
10-QAug 13, 2024-
SC 13DJul 19, 2024-
10-QMay 13, 2024-

Related Health Care companies

All Health Care →

TKNO SEC filings: frequently asked questions

Which institutions hold TKNO stock?

As of September 30, 2026, the largest Alpha Teknova, Inc. (TKNO) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($14.5 million), BlackRock ($7.1 million), Bank of America Corp ($3.3 million), Morgan Stanley ($1.5 million), State Street Corp ($1.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TKNO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Alpha Teknova, Inc. (TKNO) reported revenue of $40.5 million (up 7.4% from FY2024) and a net loss of $17.3 million. Diluted EPS was -$0.32. The figures come from the XBRL data in the 10-K.

What are the main risks in TKNO's latest 10-K?

In the 10-K filed March 2, 2026, Alpha Teknova, Inc. (TKNO) flagged: Regulatory risk: compliance with Second Amended and Restated Credit Agreement net revenue covenant of $39.0M for 2025, minimum cash requirement $8.0M. Macroeconomic exposure: 94.4% of revenue from U.S. customers, limited international diversification with only $2.3M (5.6%) sales outside U.S. in 2025. (AI summary of the Risk Factors section.)

What did TKNO report in its latest 8-K?

Alpha Teknova, Inc. (TKNO) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter fiscal 2026 results announced for period ended September 30, 2026.

What are the latest TKNO SEC filings?

Alpha Teknova, Inc. (TKNO) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on July 16, 2026.

What is TKNO's SEC CIK number?

Alpha Teknova, Inc. (TKNO)'s SEC Central Index Key (CIK) is 1850902. EDGAR lists every TKNO filing under that number.

Ask anything about TKNO

The research agent reads TKNO's filings, financials, insider trades and 13F holders, then answers with sources.